 The study design includes three parallel phase II studies, all with the same rules for patient selection and outcome assessment. In the two studies of cisplatin-based doublets, a dose-finding phase is planned, with subsequent cohorts of 6 patients treated with increasing doses of cisplatin 50-60-70 mgm2. Following this phase, patients will be assigned to the three studies through a randomization procedure, to reduce selection biases. 